Shots:

• The BT Designation is based on the P-II CHRONOS-1 study which involves assessing of 25 patients with relapsed or refractory MZL who have received at least two prior therapies
• The study resulted in ORR of overall iNHL population (n=142) was 59.2%- while the MZL patients (23%)- @18 mos. ORR (60.6% and 78.3%) in FAS population and MZL histology
• Aliqopa is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity against PI3K-α and PI3K-δ isoforms expressed in malignant B cells. Additionally- Bayer is conducting two P-III studies CHRONOS-3 and CHRONOS-4 evaluating the safety and efficacy of Aliqopa

Click here ­ to­ read full press release/ article | Ref: Bayer | Image: Bayer